BioSpace News Archive

Endo International plc (NASDAQ: ENDP) will announce its second-quarter 2019 financial results on August 6, 2019 and members of its senior management team will host a conference call and webcast at 7:30 a.m. ET before the U.S. financial markets open.

UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group (NYSE: UNH), are taking action to help people who may be affected by severe weather and flooding across parts of Louisiana, Texas and Mississippi as a result of Tropical Storm Barry.

More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at The Vision Center at Children’s Hospital Los Angeles have successfully completed the procedure on an additional 13 patients.

FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions

Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.

In a breakthrough for research fields as diverse as diabetes, atherosclerosis and biofuels, themass, concentration, volume, and surface area of individual lipid droplets have been measured in live, unstained cells for the first time using a Tomocube Holotomography (HT) microscope.

MassBio® today announced that Bayer has awarded a Fellowship to L Stem Therapeutics. Bayer’s contribution to the fellowship includes six months of workspace in LifeHub Boston, Bayer’s innovation space that convenes the brightest minds and diverse communities to collectively solve solutions to complex health challenges

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new data from post-hoc analyses of its PROMISE-1 and PROMISE-2 Phase 3 clinical trials for eptinezumab, an investigational monoclonal antibody developed for the prevention of migraine

Female leaders now represent 50 percent of the Blue Cross executive leadership team

New Whidbey Island base will serve Island County, as well as the broader Puget Sound region